Log in
Enquire now
‌

US Patent 11052112 Compositions and methods for treating cancer with anti-BCMA immunotherapy

Patent 11052112 was granted and assigned to Lentigen on July, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Lentigen
Lentigen
Current Assignee
Lentigen
Lentigen
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11052112
Patent Inventor Names
Zhongyu Zhu0
Boro Dropulic0
Dina Schneider0
Leah Marie Alabanza0
Bang Khoa Vu0
Date of Patent
July 6, 2021
Patent Application Number
16888020
Date Filed
May 29, 2020
Patent Citations
‌
US Patent 10294304 Chimeric antigen receptors targeting B-cell maturation antigen
Patent Primary Examiner
‌
Maria Marvich
Patent abstract

Chimeric antigen receptors containing BCMA antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11052112 Compositions and methods for treating cancer with anti-BCMA immunotherapy

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.